期刊
ONCOLOGIST
卷 18, 期 4, 页码 430-438出版社
OXFORD UNIV PRESS
DOI: 10.1634/theoncologist.2012-0388
关键词
Hepatocellular carcinoma; Vascular endothelial growth factor; VEGF; FGF; Angiogenesis
类别
资金
- Bristol-Myers Squibb
Hepatocellular carcinoma (HCC) is a significant cause of death worldwide. HCC is a highly vascular tumor, and proangiogenic cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor may play crucial roles in this disease. Sorafenib, a multikinase inhibitor that blocks VEGF and PDGF signaling, was the first systemic therapy to demonstrate improved survival in patients with advanced HCC. Several other drugs targeting VEGF are in development. Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed. The Oncologist 2013;18:430-438
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据